Hi Suckii,
The 18.7M includes around $4M of tax rebates. So normal trading revenue of 14.7M.
To me $10M a quarter is a number that stops the losses and confirms market penetration/performance of the ADAPT technology. This is why I expect Admedus to forecast and deliver revenue of over $40M next year following a similar pattern to NAN.
At $40M revenue and a small profit the market can relax and value Admedus with some more confidence.
We need to see evidence of solid traction in ADAPT sales in the last two quarters this year so we hit the ground running in FY18.
"Take a Closer Look", page-385
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
-0.150(1.48%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.26 | $10.35 | $9.80 | $295.8K | 29.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 22 | $9.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.00 | 2758 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |